STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Stereotaxis, Inc. ( STXS ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for joining us for Stereotaxis' Third Quarter 2025 Earnings Conference Call.
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Operator Good afternoon.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.07 per share a year ago.
Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know
Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Stereotaxis: Recurring Revenue Inflection
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin disposables and platform launches fueling a shift to an annuity-like model. Consensus underestimates top-line growth; I model $51M FY26E revenue, supported by robust operating momentum and innovation pipeline.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2025 Earnings Conference Call.
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
